132 related articles for article (PubMed ID: 20153903)
1. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.
Karussis D; Teitelbaum D; Sicsic C; Brenner T;
J Neuroimmunol; 2010 Mar; 220(1-2):125-30. PubMed ID: 20153903
[TBL] [Abstract][Full Text] [Related]
2. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis.
Salama HH; Hong J; Zang YC; El-Mongui A; Zhang J
Brain; 2003 Dec; 126(Pt 12):2638-47. PubMed ID: 12937077
[TBL] [Abstract][Full Text] [Related]
3. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study.
Farina C; Wagenpfeil S; Hohlfeld R
J Neurol; 2002 Nov; 249(11):1587-92. PubMed ID: 12420101
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis.
Sanna A; Fois ML; Arru G; Huang YM; Link H; Pugliatti M; Rosati G; Sotgiu S
Clin Exp Immunol; 2006 Feb; 143(2):357-62. PubMed ID: 16412061
[TBL] [Abstract][Full Text] [Related]
5. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.
Basile E; Gibbs E; Aziz T; Oger J
J Neuroimmunol; 2006 Aug; 177(1-2):161-6. PubMed ID: 16765453
[TBL] [Abstract][Full Text] [Related]
6. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?
Bar-Or A; Oger J; Gibbs E; Niino M; Aziz T; Renoux C; Alatab S; Shi FD; Campagnolo D; Jalili F; Rhodes S; Yamashita T; Fan B; Freedman MS; Panitch H; Arnold DL; Vollmer T
Mult Scler; 2009 Aug; 15(8):959-64. PubMed ID: 19667022
[TBL] [Abstract][Full Text] [Related]
7. The use of glatiramer acetate in the treatment of multiple sclerosis.
Wolinsky JS
Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
[TBL] [Abstract][Full Text] [Related]
8. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.
Teitelbaum D; Brenner T; Abramsky O; Aharoni R; Sela M; Arnon R
Mult Scler; 2003 Dec; 9(6):592-9. PubMed ID: 14664472
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis.
Sellebjerg F; Hedegaard CJ; Krakauer M; Hesse D; Lund H; Nielsen CH; Søndergaard HB; Sørensen PS
Mult Scler; 2012 Mar; 18(3):305-13. PubMed ID: 22020419
[TBL] [Abstract][Full Text] [Related]
11. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL
Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
[TBL] [Abstract][Full Text] [Related]
12. Do antibodies to myelin basic protein isolated from multiple sclerosis cross-react with measles and other common virus antigens?
Bernard CC; Townsend E; Randell VB; Williamson HG
Clin Exp Immunol; 1983 Apr; 52(1):98-106. PubMed ID: 6190599
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients.
Mosley RL; Gordon PH; Hasiak CM; Van Wetering FJ; Mitsumoto H; Gendelman HE
Amyotroph Lateral Scler; 2007 Aug; 8(4):235-42. PubMed ID: 17653922
[TBL] [Abstract][Full Text] [Related]
14. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Schrempf W; Ziemssen T
Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
[TBL] [Abstract][Full Text] [Related]
15. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones.
Meinl E; Weber F; Drexler K; Morelle C; Ott M; Saruhan-Direskeneli G; Goebels N; Ertl B; Jechart G; Giegerich G
J Clin Invest; 1993 Dec; 92(6):2633-43. PubMed ID: 7504690
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen T; Schrempf W
Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
[TBL] [Abstract][Full Text] [Related]
17. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S
Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604
[TBL] [Abstract][Full Text] [Related]
18. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid.
Hestvik AL; Skorstad G; Price DA; Vartdal F; Holmoy T
Mult Scler; 2008 Jul; 14(6):749-58. PubMed ID: 18611988
[TBL] [Abstract][Full Text] [Related]
19. [Significance of neutralizing antibodies to immunomodulatory therapy and their laboratory analysis in multiple sclerosis].
Seres E; Vécsei L
Ideggyogy Sz; 2006 May; 59(5-6):156-62. PubMed ID: 16786710
[TBL] [Abstract][Full Text] [Related]
20. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
Moreau T
J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]